SEC Form 4 · accession 0001493152-26-027054
Cocrystal Pharma, Inc. · COCP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Sapirstein
Officer — Chief Executive Officer
Period of report
Jun 3, 2026
Accepted (ET)
Jun 3, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001412486
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $1.12 | Jun 3, 2026 | A | 235,000 | A | — | Jun 3, 2036 | Common Stock | 235,000 | 235,000 | D |
Explanation of responses
- F1The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options vest in four equal annual installments, with the first such installment to vest on June 3, 2027, subject in each case to continued employment with the Issuer on the applicable vesting date and subject to potential accelerated vesting upon a Change in Control or termination for Cause, as such terms are defined in the 2025 Equity Incentive Plan.